Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ATM |
Variant | V1841I |
Impact List | missense |
Protein Effect | no effect - predicted |
Gene Variant Descriptions | ATM V1841I does not lie within any known functional domains of the Atm protein (UniProt.org). V1841I restores viability of ATM-deficient cells upon irradiation in culture (PMID: 29059438), and therefore, is predicted to have no effect on Atm protein function. |
Associated Drug Resistance | |
Category Variants Paths |
ATM mutant ATM V1841I |
Transcript | NM_000051.4 |
gDNA | chr11:g.108304699G>A |
cDNA | c.5521G>A |
Protein | p.V1841I |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017017789 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_006718843.4 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_047426975.1 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_017017790.2 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_006718843.5 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
NM_001351834.1 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
NM_001351834.2 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_005271562 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_005271562.5 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_005271561 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_011542840 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_017017790.3 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_011542843.3 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
NM_000051.4 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_006718843 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_017017789.2 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_005271562.6 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_011542840.3 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_011542843 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
NM_000051 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_047426976.1 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_017017791 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_017017790 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_011542843.2 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_011542840.4 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
XM_017017791.1 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
NM_000051.3 | chr11:g.108304699G>A | c.5521G>A | p.V1841I | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM V1841I | neuroblastoma | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Lynparza (olaparib) treatment of neuroblastoma cells in culture, transfected with Atm V1841I, resulted in decreased cell viability as compared to cells carrying wild-type Atm (PMID: 29059438). | 29059438 |